Novo Nordisk Return on Tangible Equity 2012-2026 | NVO
Current and historical return on tangible equity values for Novo Nordisk (NVO) over the last 10 years. Return on tangible equity can be defined as the amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity.
Unlock Macrotrends Premium
Start 7-Day Free Trial
Novo Nordisk Return On Tangible Equity Historical Data
Date
TTM Net Income
Tangible Equity
Return on Tangible Equity
2026-03-31
$19.02B
$10.05B
189.14%
2025-12-31
$15.51B
$8.22B
188.71%
2025-09-30
$15.29B
$6.97B
219.32%
2025-06-30
$16.18B
$6.93B
233.62%
2025-03-31
$15.04B
$6.69B
224.72%
2024-12-31
$14.64B
$7.09B
206.41%
2024-09-30
$13.79B
$7.60B
181.57%
2024-06-30
$13.05B
$6.52B
200.07%
2024-03-31
$12.99B
$5.92B
219.63%
2023-12-31
$12.15B
$5.55B
219.11%
2023-09-30
$10.84B
$5.01B
216.60%
2023-06-30
$9.51B
$4.65B
204.42%
2023-03-31
$8.57B
$4.27B
200.90%
2022-12-31
$7.86B
$4.08B
192.51%
2022-09-30
$7.66B
$4.05B
189.37%
2022-06-30
$7.63B
$4.85B
157.52%
2022-03-31
$7.70B
$5.61B
137.06%
2021-12-31
$7.60B
$6.29B
120.89%
2021-09-30
$7.45B
$6.82B
109.12%
2021-06-30
$7.14B
$6.98B
102.24%
2021-03-31
$6.74B
$7.15B
94.29%
2020-12-31
$6.46B
$7.40B
87.23%
2020-09-30
$6.23B
$7.71B
80.83%
2020-06-30
$6.13B
$7.52B
81.50%
2020-03-31
$6.01B
$7.29B
82.34%
2019-12-31
$5.84B
$7.10B
82.24%
2019-09-30
$5.62B
$6.95B
80.92%
2019-06-30
$5.51B
$6.83B
80.65%
2019-03-31
$5.72B
$6.85B
83.49%
2018-12-31
$5.91B
$6.91B
85.43%
2018-09-30
$6.16B
$6.90B
89.36%
2018-06-30
$6.30B
$6.97B
90.28%
2018-03-31
$6.11B
$6.87B
88.96%
2017-12-31
$5.79B
$6.56B
88.36%
2017-09-30
$5.73B
$6.37B
89.87%
2017-06-30
$5.65B
$6.06B
93.21%
2017-03-31
$5.69B
$5.91B
96.39%
2016-12-31
$5.64B
$5.86B
96.16%
2016-09-30
$5.59B
$5.95B
93.95%
2016-06-30
$5.37B
$6.06B
88.62%
2016-03-31
$5.09B
$5.91B
86.05%
2015-12-31
$5.19B
$5.78B
89.75%
2015-09-30
$5.08B
$5.85B
86.81%
2015-06-30
$4.98B
$5.92B
84.14%
2015-03-31
$5.03B
$6.13B
82.05%
2014-12-31
$4.72B
$6.43B
73.39%
2014-09-30
$4.74B
$6.52B
72.60%
2014-06-30
$4.72B
$6.56B
71.94%
2014-03-31
$4.61B
$6.43B
71.75%
2013-12-31
$4.49B
$6.39B
70.19%
2013-09-30
$4.38B
$6.26B
70.04%
2013-06-30
$4.20B
$6.03B
69.58%
2013-03-31
$3.94B
$5.85B
67.42%
2012-12-31
$3.70B
$5.78B
64.08%
2012-09-30
$3.53B
$5.77B
61.18%
2012-06-30
$3.36B
$5.95B
56.56%
2012-03-31
$3.24B
$6.37B
50.84%
2011-12-31
$3.16B
$6.53B
48.41%
2011-09-30
$3.06B
$6.44B
47.56%
2011-06-30
$2.94B
$6.25B
47.09%
2011-03-31
$2.77B
$5.92B
46.79%
2010-12-31
$2.62B
$5.88B
44.60%
2010-09-30
$2.35B
$5.92B
39.74%
2010-06-30
$2.23B
$6.12B
36.46%
2010-03-31
$2.15B
$6.25B
34.42%
2009-12-31
$2.03B
$6.10B
33.35%
2009-09-30
$1.99B
$6.06B
32.77%
2009-06-30
$1.98B
$6.02B
32.86%
2009-03-31
$1.76B
$6.19B
28.46%
2008-12-31
$1.72B
$6.40B
26.89%
2008-09-30
$1.50B
$6.26B
23.93%
2008-06-30
$1.36B
$6.18B
22.08%
2008-03-31
$1.69B
$5.97B
28.38%
2007-12-31
$1.56B
$5.71B
27.24%
2007-09-30
$1.66B
$5.50B
30.24%
2007-06-30
$1.56B
$5.18B
30.12%
2007-03-31
$1.19B
$4.89B
24.35%
2006-12-31
$1.09B
$4.68B
23.19%
2006-09-30
$1.00B
$4.57B
21.85%
2006-06-30
$1.00B
$4.45B
22.42%
2006-03-31
$0.99B
$4.28B
23.21%
2005-12-31
$1.02B
$4.31B
23.56%
2005-09-30
$1.06B
$4.27B
24.91%
2005-06-30
$0.97B
$4.26B
22.72%
2005-03-31
$0.90B
$4.24B
21.09%
2004-12-31
$0.86B
$4.12B
20.81%
2004-09-30
$0.81B
$3.98B
20.44%
2004-06-30
$0.78B
$3.84B
20.30%
2004-03-31
$0.76B
$3.73B
20.49%
2003-12-31
$0.74B
$3.55B
20.93%
2003-09-30
$0.74B
$3.39B
21.71%
2003-06-30
$0.70B
$2.48B
28.14%
2003-03-31
$0.64B
$2.25B
28.35%
2002-12-31
$0.58B
$2.04B
28.29%
2002-09-30
$0.48B
$1.84B
26.24%
2002-06-30
$0.46B
$1.84B
25.15%
2002-03-31
$0.43B
$1.18B
36.33%
2001-12-31
$0.46B
$0.60B
76.82%
2001-09-30
$0.44B
$0.49B
88.66%
2001-06-30
$0.41B
$0.49B
83.38%
2001-03-31
$0.42B
$0.49B
85.82%
2000-12-31
$0.38B
$0.49B
78.09%
2000-09-30
$0.39B
$0.51B
75.64%
2000-06-30
$0.38B
$0.51B
75.25%
2000-03-31
$0.36B
$0.51B
70.53%
1999-12-31
$0.34B
$0.51B
66.99%
1999-09-30
$0.34B
$6.65B
5.14%
1999-06-30
$0.33B
$6.65B
4.99%
1999-03-31
$0.35B
$6.65B
5.22%
1998-12-31
$0.36B
$6.65B
5.40%
1998-09-30
$0.36B
$0.67B
53.38%
1998-06-30
$0.38B
$0.67B
56.51%
1998-03-31
$0.36B
$0.67B
53.09%
1997-12-31
$0.34B
$0.67B
49.81%
1997-09-30
$0.32B
$0.68B
47.03%
1997-06-30
$0.31B
$0.68B
44.97%
1997-03-31
$0.30B
$0.68B
44.53%
1996-12-31
$0.31B
$0.68B
45.85%
1996-09-30
$0.30B
$0.64B
46.15%
1996-06-30
$0.30B
$0.64B
46.31%
1996-03-31
$0.30B
$0.64B
46.31%
1995-12-31
$0.28B
$0.64B
43.67%
1995-09-30
$0.30B
0
0.00%
1995-06-30
$0.28B
0
0.00%
1995-03-31
$0.24B
0
0.00%
1994-12-31
$0.23B
0
0.00%
1994-09-30
$0.21B
$2.93B
7.13%
1994-06-30
$0.21B
$2.93B
7.06%
1994-03-31
$0.21B
$2.93B
7.03%
1993-12-31
$0.22B
$2.93B
7.33%
1993-09-30
$0.22B
$2.61B
8.29%
1993-06-30
$0.21B
$2.61B
7.94%
Sector
Industry
Market Cap
Revenue
Medical Large Cap Pharmaceutical $167.527B
$46.797B
Bagsv?rd, Denmark-based Novo Nordisk is a global healthcare company and a leader in the worldwide diabetes market. The company is also a key player in hemophilia care, growth hormone therapy, hormone replacement therapy and obesity.Novo Nordisk operates through two segments: Diabetes and obesity care and Biopharmaceuticals. While the Diabetes and obesity care segment covers insulins, glucagon-like peptide 1 (GLP-1), other protein-related products, obesity and oral anti-diabetic drugs, the Biopharmaceuticals segment includes hemophilia, growth hormone therapy and hormone replacement therapy.Novo Nordisk's most well-known drugs include Levemir, NovoRapid, Victoza, Ozempic, NovoMix, NovoSeven, NovoThirteen, Ryzodeg, Xultophy, Saxenda, Rybelsus, Esperoct, Sogroya and Norditropin, among several others. The company launched its first product for weight management, Saxenda, in the United States in 2015.In August 2018, Novo Nordisk announced that it has acquired all of the shares of Ziylo Ltd.
